{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:46:47Z","timestamp":1793933207573,"version":"4.8.0"},"reference-count":85,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,10,16]],"date-time":"2006-10-16T00:00:00Z","timestamp":1160956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respirology"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:p><jats:bold>Abstract:\u2003<\/jats:bold> Isoniazid, pyrazinamide and rifampicin have hepatotoxic potential, and can lead to such reactions during antituberculosis chemotherapy. Most of the hepatotoxic reactions are dose\u2010related; some are, however, caused by drug hypersensitivity. The immunogenetics of antituberculosis drug\u2010induced hepatotoxicity, especially inclusive of acetylaor phenotype polymorphism, have been increasingly unravelled. Other principal clinical risk factors for hepatotoxicity are old age, malnutrition, alcoholism, HIV infection, as well as chronic hepatitis B and C infections. Drug\u2010induced hepatic dysfunction usually occurs within the initial few weeks of the intensive phase of antituberculosis chemotherapy. Vigilant clinical (including patient education on symptoms of hepatitis) and biochemical monitoring are mandatory to improve the outcomes of patients with drug\u2010induced hepatotoxicity during antituberculosis chemotherapy. Some fluoroquinolones like ofloxacin\/levofloxacin may have a role in constituting non\u2010hepatotoxic drug regimens for management of tuberculosis (TB) in the presence of hepatic dysfunction. Isoniazid administration is currently the standard therapy for latent TB infection. Rifamycins like rifampicin or rifapentine, alone or in combination with isoniazid, may also be considered as alternatives, pending accumulation of further clinical data. During treatment of latent TB infection, regular follow up is essential to ensure adherence to therapy and facilitate clinical monitoring for hepatic dysfunction. Monitoring of liver chemistry is also required for those patients at risk of drug\u2010induced hepatotoxicity.<\/jats:p>","DOI":"10.1111\/j.1440-1843.2006.00941.x","type":"journal-article","created":{"date-parts":[[2006,10,18]],"date-time":"2006-10-18T11:26:28Z","timestamp":1161170788000},"page":"699-707","source":"Crossref","is-referenced-by-count":191,"title":["Antituberculosis drugs and hepatotoxicity"],"prefix":"10.1111","volume":"11","author":[{"given":"Wing Wai","family":"YEW","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Chiu","family":"LEUNG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,10,16]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Treatment of Tuberculosis: Guidelines for National Programmes","author":"World Health Organization.","year":"2003"},{"key":"e_1_2_6_3_2","first-page":"99","article-title":"Risk factors for hepatotoxicity during anti\u2010tuberculosis chemotherapy in Asian populations","volume":"5","author":"Yew WW","year":"2001","journal-title":"Int. J. Tuberc. Lung. Dis."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.99.2.465"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198223010-00003"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(86)90003-6"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.71.836.359"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840210407"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.96.09102026"},{"key":"e_1_2_6_10_2","first-page":"65","article-title":"The management of anti\u2010tuberculosis drug\u2010induced hepatotoxicity","volume":"5","author":"Tahaoglu K","year":"2001","journal-title":"Int. J. Tuberc. Lung. Dis."},{"key":"e_1_2_6_11_2","first-page":"699","article-title":"Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore","volume":"6","author":"Teleman MD","year":"2002","journal-title":"Int. J. Tuberc. Lung. Dis."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200206-626OC"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.167.4.603"},{"key":"e_1_2_6_14_2","first-page":"43","article-title":"Adverse drug reactions and outcome of elderly patients on anti\u2010tuberculosis chemotherapy with and without rifampicin","volume":"26","author":"Chan CH","year":"1995","journal-title":"J. Med."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2003.01.001"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199810000-00004"},{"key":"e_1_2_6_17_2","first-page":"67","article-title":"Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs","volume":"4","author":"Schreiber J","year":"1999","journal-title":"Eur. J. Med. Res."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.3109\/01480549709003881"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.50.2.213"},{"key":"e_1_2_6_20_2","first-page":"256","article-title":"Slow N\u2010acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin\u2010induced hepatotoxicity","volume":"4","author":"Ohno M","year":"2000","journal-title":"Int. J. Tuberc. Lung. Dis."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50144"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2001.02585.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2108091"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0962-8479(96)90098-2"},{"key":"e_1_2_6_25_2","first-page":"58","article-title":"Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis","volume":"129","author":"Gurumurthy P","year":"1984","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt197518170"},{"key":"e_1_2_6_27_2","first-page":"628","article-title":"The hepatic toxicity of isoniazid among rapid and slow acetylators of the drug","volume":"118","author":"Ellard GA","year":"1978","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.32102"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.51.2.132"},{"key":"e_1_2_6_30_2","first-page":"1499","article-title":"The influence of risk factors on the severity of anti\u2010tuberculosis drug\u2010induced hepatotoxicity","volume":"8","author":"Fernandez\u2010Villar A","year":"2004","journal-title":"Int. J. Tuberc. Lung. Dis."},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D525"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310129"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.6.9711039"},{"key":"e_1_2_6_34_2","first-page":"1978","article-title":"Hepatotoxicity from isoniazid and rifampin in inner\u2010city AIDS patients","volume":"90","author":"Ozick LA","year":"1995","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/13.7.1872"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199911150-00009"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199705150-00015"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.2.408"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/09595239500185071"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(83)90037-5"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.53.7.536"},{"key":"e_1_2_6_42_2","first-page":"978","article-title":"Tuberculosis management in Europe. Recommendations of a Task Force of the European Respiratory Society, the World Health Organisation, and the International Union against Tuberculosis and Lung Disease Europe Region","volume":"14","author":"ERS Task Force.","year":"1999","journal-title":"Eur. Respir. J."},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/0962-8479(94)90104-X"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91943-O"},{"key":"e_1_2_6_45_2","first-page":"534","article-title":"Study Group of Severe Hepatotoxicity due to Anti\u2010tuberculosis Drugs. Severe hepatotoxicity due to anti\u2010tuberculosis drugs in Spain","volume":"9","author":"Tost JR","year":"2005","journal-title":"Int. J. Tuberc. Lung. Dis."},{"key":"e_1_2_6_46_2","first-page":"173","article-title":"Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction","volume":"12","author":"Yew WW","year":"1992","journal-title":"Int. J. Clin. Pharmacol. Res."},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200001150-00013"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2004.08.114"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.95.08081384"},{"key":"e_1_2_6_50_2","first-page":"79","article-title":"Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction","volume":"21","author":"Yew WW","year":"1995","journal-title":"Drugs Exp. Clin. Res."},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2001.02570.x"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.3.1406"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.151.6.7767552"},{"key":"e_1_2_6_54_2","first-page":"905","article-title":"Successful treatment of multidrug\u2010resistant tuberculosis following drug\u2010induced hepatic necrosis requiring liver transplant","volume":"8","author":"Marra F","year":"2004","journal-title":"Int. J. Tuberc. Lung. Dis."},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)90846-S"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02090381"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00330-7"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2004.11.003"},{"key":"e_1_2_6_59_2","first-page":"735","article-title":"Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection\u2014United States, 2003","volume":"52","author":"Centers for Disease Control and Prevention\/American Thoracic Society.","year":"2003","journal-title":"MMWR"},{"issue":"6","key":"e_1_2_6_60_2","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"American Thoracic Society\/Centers for Disease Control and Prevention.","year":"2000","journal-title":"MMWR"},{"key":"e_1_2_6_61_2","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow\u2010up in the IUAT trial","volume":"60","author":"International Union Against Tuberculosis Committee on Prophylaxis.","year":"1982","journal-title":"Bull. World Health Organ."},{"key":"e_1_2_6_62_2","first-page":"991","article-title":"Isoniazid\u2010related hepatitis: a US Public Health Service cooperative surveillance study","volume":"117","author":"Kopanoff DE","year":"1978","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.11.1014"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1972.106.3.357"},{"key":"e_1_2_6_65_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.1.36"},{"key":"e_1_2_6_66_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.155.5.9154885"},{"key":"e_1_2_6_67_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.5.8912767"},{"key":"e_1_2_6_68_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200404-478OC"},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.55.11.887"},{"key":"e_1_2_6_70_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709183371201"},{"key":"e_1_2_6_71_2","doi-asserted-by":"publisher","DOI":"10.1086\/427802"},{"key":"e_1_2_6_72_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.150.5.7952564"},{"key":"e_1_2_6_73_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.9.2126"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200512-1953OC"},{"key":"e_1_2_6_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)06532-X"},{"key":"e_1_2_6_76_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.11.1445"},{"key":"e_1_2_6_77_2","doi-asserted-by":"publisher","DOI":"10.1086\/444463"},{"key":"e_1_2_6_78_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.22.2776"},{"key":"e_1_2_6_79_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-8-200210150-00007"},{"key":"e_1_2_6_80_2","first-page":"276","article-title":"Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?","volume":"9","author":"Tortajada C","year":"2005","journal-title":"Int. J. Tuberc. Lung. Dis."},{"key":"e_1_2_6_81_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.6.2112"},{"key":"e_1_2_6_82_2","first-page":"171","article-title":"Controlled trial of four thrice\u2010weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis","volume":"1","author":"Hong Kong\/British Medical Research Council.","year":"1981","journal-title":"Lancet"},{"key":"e_1_2_6_83_2","doi-asserted-by":"publisher","DOI":"10.1086\/499244"},{"key":"e_1_2_6_84_2","doi-asserted-by":"publisher","DOI":"10.1086\/422645"},{"key":"e_1_2_6_85_2","first-page":"334","article-title":"Observations on the combined use of pyrazinamide (Aldinamide) and isoniazid in the treatment of pulmonary tuberculosis; a clinical study","volume":"69","author":"Campagna M","year":"1954","journal-title":"Am. Rev. Tuberc."},{"key":"e_1_2_6_86_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00006205"}],"container-title":["Respirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1843.2006.00941.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1843.2006.00941.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T04:33:47Z","timestamp":1697258027000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1843.2006.00941.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,16]]},"references-count":85,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1111\/j.1440-1843.2006.00941.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1843.2006.00941.x","archive":["Portico"],"relation":{},"ISSN":["1323-7799","1440-1843"],"issn-type":[{"value":"1323-7799","type":"print"},{"value":"1440-1843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,16]]}}}